Three notes:
1. Results demonstrated that Linzess, developed by Ironwood Pharmaceuticals, was associated with a significant improvement in abdominal score compared to placebo in adult IBS-C patients.
2. The abdominal score includes symptoms that IBS-C patients identify as bothersome and important to treat, such as bloating, pain and discomfort.
3. Study results may “help physicians and patients have a more comprehensive discussion about these bothersome symptoms and ways to manage them,” Lin Chang, MD, vice chief of digestive diseases at the University of California Los Angeles, said in a June 16 news release.
Click here for more details on the clinical trial.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
